EyePoint Pharmaceuticals, Inc. — Director's Dealing 2018

May 14, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2018-05-07

Reporting Person: Barry James J (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-05-07	Common Stock	M	12500	—	Acquired	12500	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-05-07	Deferred Stock Units	$	M	12500	Disposed		Common Stock (12500)	Direct

Footnotes

F1: Each deferred stock unit represents the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc.

F2: On December 15, 2017, the reporting person was granted 12,500 deferred stock units, which deferred stock units vested in full in connection with the effectiveness of Mr. Barry's resignation from the Board on May 7, 2018.